Valneva SE on Oct. 18 said the company’s experimental Covid-19 vaccine demonstrated efficacy “at least as good, if not better” than AstraZeneca’s shot in a late-stage trial comparing the two, with significantly fewer adverse side effects.
AstraZeneca announced positive high-level data from the HIMALAYA Phase III trial of a single, high priming dose of tremelimumab plus Imfinzi (durvalumab) in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, who had not had previous systemic therapy and were not eligible for localized treatment.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.
Europe’s drug regulator started a real-time review of AstraZeneca’s antibody-based Covid-19 therapy, the first protective shot other than vaccines against coronavirus.
In October 2020, the government recommended against kids going trick-or-treating for Halloween out of fear of Covid-19 spread. For Halloween 2021, kids have been given the green light to knock on doors.
AstraZeneca’s antibody cocktail against Covid-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
AstraZeneca produced one of the global vaccines to treat COVID-19, but the company’s growth in the future will still rely on the oncology and respiratory areas.
The number of new Covid-19 infections dropped during the past month throughout the Americas, even though only 37 percent of the people in Latin America and the Caribbean are fully vaccinated, the Pan American Health Organization (PAHO) said on Oct. 6.
AstraZeneca agreed to pay a $560,000 settlement to resolve allegations of gender and racial discrimination filed by employees at the company’s Wilmington, Del. headquarters.
AstraZeneca requested emergency use authorization from U.S. regulators for the company’s new treatment to prevent Covid-19 for people who respond poorly to vaccines because of a weakened immune system.
